Jubilant Pharmova Ltd

Integrated Filing — Corporate Governance (NSE XBRL)

Company Home Dashboard NSE Viewer

Filing Summary

Company
Jubilant Pharmova Limited
Symbol
JUBLPHARMA
Quarter Ended
31-Mar-2026
Submission
New

General Disclosures

Advertisements As Per Regulation471
Yes
Annual Return As Provided Under Section92Of The Companies Act2013
Yes
Approval For Material Related Party Transactions
Not Applicable
Approval Of The Board And Shareholders For Compensation Or Profit Sharing
Not Applicable
Audio Or Video Recordings And Transcripts Of Post Earinings Or Quarterly Calls
Yes
Board Composition
Yes
Code Of Conduct
Yes
Compliance Certificate
Yes
Compliance With Sub Regulation3Of Regulation46With Respect To Accuracy Of Disclosures On The Website And Timely Updation
Yes
Confirmation That The Disclosures Are In A Separate Section As Specified In Sub Regulation2Of Regulation46
Yes
Credit Rating Or Revision In Credit Rating Obtained
Yes
Date Of End Of Financial Year
31-Mar-2026
Date Of End Of Reporting Period
31-Mar-2026
Date Of Signing
29-Apr-2026
Date Of Start Of Financial Year
01-Apr-2025
Designation Of Person
Company Secretary and Compliance Officer
Designation Of Person Affirmations
Company Secretary and Compliance Officer
Designation Of Person For Annual Affirmations
Company Secretary and Compliance Officer
Designation Of Person For Quartely Affirmations
Company Secretary and Compliance Officer
Details Of Agreements Entered Into With The Media Companies And Or Their Associates
Not Applicable
Details Of Business
Yes
Details Of Establishment Of Vigil Mechanism Or Whistle Blower Policy
Yes
Disclosure Of Contact Details Of KMP Who Are Authorized For The Purpose Of Determining Materiality Under Sub Regulation5Of Regulation30
Yes
Disclosure Of Related Party Transactions On Consolidated Basis
Yes
Disclosure Web Link Of Annual Return As Provided Under Section92Of The Companies Act2013Is Placed
https://www.jubilantpharmova.com/investors/financials/annual-return
Disclosure Web Link Of Audio Or Video Recordings And Transcripts Of Post Earinings Or Quarterly Calls Is Placed
https://www.jubilantpharmova.com/investors/jubilant-pharmova-investors-meets
Disclosure Web Link Of Company At Advertisements As Per Regulation471Is Placed
https://www.jubilantpharmova.com/investors/disclosure/notices-given-to-shareholders-by-advertisement
Disclosure Web Link Of Company At Details Of Non Compliance Of New Name And The Old Name Of The Listed Entity Is Placed
https://www.jubilantpharmova.com/investors/investor-information/change-of-name
Disclosure Web Link Of Company At Dividend Distribution Policy As Per Regulation43A1Is Placed
https://www.jubilantpharmova.com/investors/corporate-governance/policies-and-codes/dividend-distribution-policy
Disclosure Web Link Of Company At Materiality Policy As Per Sub Regulation4Regulation30Is Placed
https://www.jubilantpharmova.com/investors/corporate-governance/policies-and-codes/policy-for-determination-of-materiality-of-events-and-information
Disclosure Web Link Of Company At Separate Audited Financial Statements Of Each Subsidiary Of The Listed Entity Is Placed
https://www.jubilantpharmova.com/investors/financials/subsidiaries-accounts
Disclosure Web Link Of Company At Which Credit Rating Or Revision In Credit Rating Obtained Is Placed
https://www.jubilantpharmova.com/investors/investor-information/credit-ratings
Disclosure Web Link Of Company At Which Details Of Business Is Placed
https://www.jubilantpharmova.com/about-us/company-profile
Disclosure Web Link Of Company At Which Details Of Establishment Of Vigil Mechanism Or Whistle Blower Policy Is Placed
https://www.jubilantpharmova.com/investors/corporate-governance/policies-and-codes/whistle-blower-policy
Disclosure Web Link Of Company At Which Financial Results Is Placed
https://www.jubilantpharmova.com/investors/financials/quarterly-results
Disclosure Web Link Of Company At Which Policy For Determining Material Subsidiaries Is Placed
https://www.jubilantpharmova.com/investors/corporate-governance/policies-and-codes/policy-for-determining-material-subsidiaries
Disclosure Web Link Of Company At Which Policy On Dealing With Related Party Transactions Is Placed
https://www.jubilantpharmova.com/investors/corporate-governance/policies-and-codes/policy-on-rpts
Disclosure Web Link Of Company At Which Shareholding Pattern Is Placed
https://www.jubilantpharmova.com/investors/investor-information/share-holding-pattern
Disclosure Web Link Of Compliance With Sub Regulation3Of Regulation46With Respect To Accuracy Of Disclosures On The Website And Timely Updation Is Placed
https://www.jubilantpharmova.com/investors/disclosure-under-regulation-46-and-62-of-the-LODR
Disclosure Web Link Of Confirmation That The Disclosures Are In A Separate Section As Specified In Sub Regulation2Of Regulation46Is Placed
https://www.jubilantpharmova.com/investors/disclosure-under-regulation-46-and-62-of-the-LODR
Disclosure Web Link Of Disclosure Of Contact Details Of KMP Who Are Authorized For The Purpose Of Determining Materiality Under Sub Regulation5Of Regulation30Is Placed
https://www.jubilantpharmova.com/investors/investor-contact/kmp-reg30
Disclosure Web Link Of Disclosures Under Sub Regulation8Of Regulation30Is Placed
https://www.jubilantpharmova.com/investors/disclosure/disclsoures-under-30_8
Disclosure Web Link Of Employee Benefit Scheme Documents Framed In Terms Of SEBI Share Based Employee Benefits And Sweat Equity Regulations2021Is Placed
https://www.jubilantpharmova.com/Uploads/image/2491imguf_jpm-employee-stock-option-plan-2018.pdf
Disclosure Web Link Of Memorandum Of Association And Articles Of Association Is Placed
https://www.jubilantpharmova.com/investors/disclosure-under-regulation-46-and-62-of-the-LODR
Disclosure Web Link Of Schedule Of Analyst Or Institutional Investor Meet And Presentation Prepared By Listed Entity For Analyst Or Institutional Investor Meet Is Placed
https://www.jubilantpharmova.com/investors/jubilant-pharmova-investors-meet-2025
Disclosure Web Link Of Secretarial Compliance Report Is Placed
https://www.jubilantpharmova.com/investors/disclosure/annual-secretarial-complaince-report
Disclosures Under Sub Regulation8Of Regulation30
Yes
Dividend Distribution Policy As Per Regulation43A1
Yes
Employee Benefit Scheme Documents Framed In Terms Of SEBI Share Based Employee Benefits And Sweat Equity Regulations2021
Yes
Fees Or Compensation
Yes
Financial Results
Yes
Is SCORESID Available
Yes
ISIN
INE700A01033
Market Capitalisation As Per Immediate Previous Financial Year
Top 500 listed entities
Materiality Policy As Per Sub Regulation4Regulation30
Yes
Memorandum Of Association And Articles Of Association
Yes
Minimum Information
Yes
MSEI Symbol
NOTLISTED
Name Of Signatory
Naresh Kapoor
Name Of Signatory Affirmations
Naresh Kapoor
Name Of Signatory For Annual Affirmations
NARESH KAPOOR
Name Of Signatory For Quartely Affirmations
Naresh Kapoor
Name Of The Company
JUBILANT PHARMOVA LIMITED
New Name And The Old Name Of The Listed Entity
Yes
Other Corporate Governance Requirements With Respect To Subsidiary Of Listed Entity
Yes
Place
Noida
Plans For Orderly Succession For Appointments
Yes
Policy For Determining Material Subsidiaries
Yes
Policy For Related Party Transaction
Yes
Policy On Dealing With Related Party Transactions
Yes
Reason For Part F Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Loans Or Guarantees Or Comfort Letters Or Securities Etc Is Not Applicable To The Entity
There was no loans / guarantees / comfort letters / securities etc. for the quarter ended March 31, 2026, requiring disclosure under this report.
Recommendation Of Board
Yes
Reporting Quarter
Yearly
Review Of Compliance Reports
Yes
Risk Assessment And Management
Yes
Schedule Of Analyst Or Institutional Investor Meet And Presentation Prepared By Listed Entity For Analyst Or Institutional Investor Meet
Yes
SCORES Registration ID
J00122
Scrip Code
530019
Secretarial Compliance Report
Yes
Separate Audited Financial Statements Of Each Subsidiary Of The Listed Entity
Yes
Shareholding Pattern
Yes
Statements Of Deviations Or Variations As Specified In Regulation32
Not Applicable
Symbol
JUBLPHARMA
The Listed Entity Has Approved Material Subsidiary Policy And The Corporate Governance Requirements With Respect To Subsidiary Of Listed Entity Have Been Complied
Yes
Type Of Company
Equity
Type Of Submission
Original
Vacancies In Respect Key Managerial Personnel
Yes
Vigil Mechanism
Yes
Whether As Per Sub Regulation2ba Of Regulation27Of SEBILODR There Has Been Cyber Security Incidents During The Quarter
No
Whether Part A Of Annexure I Of The SEBI Circular Dated31December2024Related To Compliance Report On Corporate Governance Is Applicable To The Entity
Yes
Whether Part F Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Loans Or Guarantees Or Comfort Letters Or Securities Etc Is Applicable To The Entity
No

Additional Disclosures

Entry D_MeetingBOD1
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingBOD2
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit1
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit2
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit3
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit4
Whether Requirement Of Quorum Met
Yes
Entry D_MeetingComit5
Whether Requirement Of Quorum Met
Yes
Official NSE disclosure viewer

If the viewer does not load, use the NSE Viewer button above to open it in a new tab.

Board Composition — Entity Disclosures

Disclosure Of Notes On Composition Of Board Of Directors Explanatory Text Block
1. Mr. Arjun S. Bhartia is Joint MD of the Company. Since there is no option available for Joint MD in Column L, category 3 of directors, therefore we have selected Managing Director as the designation of Mr. Arjun S. Bhartia. 2. As per Circular Ref. No. NSE/CML/2023/31 dated April 10, 2023 issued by the NSE, the Company has considered the No. of post of Chairperson in Audit/Stakeholder Committee held includes public limited companies whether listed or not.
The Composition Of Board Of Directors Is In Terms Of Sebi Regulations2015
Yes
Chairperson Related to MD / CEO
Yes
Regular Chairperson
Yes

Composition of Board of Directors

SrTitleDirectorPANDINCategory 1Category 2Category 3Date of BirthDisqualifiedStatusSpecial ResolutionSpecial Resolution DateInitial AppointmentRe-appointmentTenure (months)Listed DirectorshipsIndependent DirectorshipsAudit / Stakeholder MembershipsAudit / Stakeholder Chair Posts
1MrShyam Sunder Bhartia******00010484Non-Executive - Non Independent DirectorChairperson related to Promoter09-Nov-1952NoActiveNot Applicable21-Jun-197828-Jan-19994000
2MrHari Shanker Bhartia******00010499Non-Executive - Non Independent DirectorNot Applicable12-Dec-1956NoActiveNot Applicable01-Nov-198301-Apr-20226320
3MrSushil Kumar Roongta******00309302Non-Executive - Independent DirectorNot Applicable09-May-1950NoActiveYes22-Sep-202123-May-201723-May-20221066671
4MrVivek Mehra******00101328Non-Executive - Independent DirectorNot Applicable21-Apr-1955NoActiveNot Applicable23-May-201723-May-20221066694
5MrArun Seth******00204434Non-Executive - Independent DirectorNot Applicable19-Nov-1951NoActiveYes31-Aug-202322-Oct-201822-Oct-20238944105
6MrShirish Gundopant Belapure******02219458Non-Executive - Independent DirectorNot Applicable19-Jul-1953NoActiveNot Applicable07-Mar-202307-Mar-2023374431
7MrPriyavrat Bhartia******00020603Executive DirectorNot ApplicableMD04-Oct-1976NoActiveNot Applicable23-May-201701-Jun-20236040
8MrArjun Shanker Bhartia******03019690Executive DirectorNot ApplicableMD21-Feb-1987NoActiveNot Applicable23-May-201701-Jun-20233000
9MsShivpriya Nanda******01313356Non-Executive - Independent DirectorNot Applicable04-May-1963NoActiveNot Applicable01-Apr-202401-Apr-2024242241
10MrHarsh Mahajan******00824227Non-Executive - Independent DirectorNot Applicable31-Mar-1959NoActiveNot Applicable01-Apr-202401-Apr-2024241110

Committee Disclosures

Entry CompComit100
Date of Appointment
21-May-2024
Entry CompComit101
Date of Appointment
21-May-2024
Entry CompComit102
Date of Appointment
21-May-2024
Entry CompComit122
Date of Appointment
21-May-2024
Entry CompComit123
Date of Appointment
17-Jan-2018
Entry CompComit124
Date of Appointment
17-Jan-2018
Entry CompComit125
Date of Appointment
17-Jan-2018
Entry CompComit126
Date of Appointment
02-Feb-2024
Entry CompComit127
Date of Appointment
21-May-2024
Entry CompComit128
Date of Appointment
21-May-2024
Entry CompComit14
Date of Appointment
17-Jan-2018
Entry CompComit15
Date of Appointment
02-Feb-2024
Entry CompComit16
Date of Appointment
21-May-2024
Entry CompComit17
Date of Appointment
21-May-2024
Entry CompComit41
Date of Appointment
17-Jan-2018
Entry CompComit42
Date of Appointment
26-May-2014
Entry CompComit43
Date of Appointment
17-Jan-2018
Entry CompComit44
Date of Appointment
21-May-2024
Entry CompComit68
Date of Appointment
01-Feb-2019
Entry CompComit69
Date of Appointment
02-Feb-2024
Entry CompComit70
Date of Appointment
21-May-2024
Entry CompComit71
Date of Appointment
21-May-2024
Entry CompComit95
Date of Appointment
01-Feb-2019
Entry CompComit96
Date of Appointment
01-Feb-2019
Entry CompComit97
Date of Appointment
07-Mar-2023
Entry CompComit98
Date of Appointment
29-May-2023
Entry CompComit99
Date of Appointment
29-May-2023
Entry MainD
Composition And Role Of Risk Management Committee
Yes
Composition Of Audit Committee
Yes
Composition Of Nomination And Remuneration Committee
Yes
Composition Of Stakeholder Relationship Committee
Yes
Composition Of Various Committees Of Board Of Directors
Yes
Disclosure Web Link Of Company At Which Composition Of Various Committees Of Board Of Directors Is Placed
https://www.jubilantpharmova.com/Uploads/image/2238imguf_list-commiteewise.pdf
Memberships In Committees
Yes
Prior Or Omnibus Approval Of Audit Committee For All Related Party Transactions
Yes
Risk Management Committee
Yes
Role Of Audit Committee And Information To Be Reviewed By The Audit Committee
Yes
Role Of Nomination And Remuneration Committee
Yes
Role Of Stakeholders Relationship Committee
Yes
The Committee Members Have Been Made Aware Of Their Powers Role And Responsibilities As Specified In Sebi Regulations2015
Yes
The Composition Of Audit Committee Is In Terms Of Sebi Regulations2015
Yes
The Composition Of The Nomination And Remuneration Committee Is In Terms Of Sebi Regulations2015
Yes
The Composition Of The Risk Management Committee Is In Terms Of Sebi Regulations2015
Yes
The Composition Of The Stakeholders Relationship Committee Committee Is In Terms Of Sebi Regulations2015
Yes
Whether The Audit Committee Has A Regular Chairperson
Yes
Whether The Corporate Social Responsibility Committee Has A Regular Chairperson
Yes
Whether The Nomination And Remuneration Committee Has A Regular Chairperson
Yes
Whether The Risk Management Committee Has A Regular Chairperson
Yes
Whether The Stakeholders Relationship Committee Has A Regular Chairperson
Yes

Audit Committee

Additional Position
Chairperson
Director DIN
00101328
Member Name
Vivek Mehra
Position
Non-Executive - Independent Director

Audit Committee

Additional Position
Member
Director DIN
00309302
Member Name
Sushil Kumar Roongta
Position
Non-Executive - Independent Director

Audit Committee

Additional Position
Member
Director DIN
00204434
Member Name
Arun Seth
Position
Non-Executive - Independent Director

Audit Committee

Additional Position
Member
Director DIN
01313356
Member Name
Shivpriya Nanda
Position
Non-Executive - Independent Director

Audit Committee

Audit Committee

Corporate Social Responsibility Committee

Additional Position
Chairperson
Director DIN
01313356
Member Name
Shivpriya Nanda
Position
Non-Executive - Independent Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
00309302
Member Name
Sushil Kumar Roongta
Position
Non-Executive - Independent Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
00020603
Member Name
Priyavrat Bhartia
Position
Executive Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
03019690
Member Name
Arjun Shanker Bhartia
Position
Executive Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
02219458
Member Name
Shirish Gundopant Belapure
Position
Non-Executive - Independent Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
00204434
Member Name
Arun Seth
Position
Non-Executive - Independent Director

Corporate Social Responsibility Committee

Additional Position
Member
Director DIN
00824227
Member Name
Harsh Mahajan
Position
Non-Executive - Independent Director

Corporate Social Responsibility Committee

Nomination and remuneration committee

Additional Position
Chairperson
Director DIN
00309302
Member Name
Sushil Kumar Roongta
Position
Non-Executive - Independent Director

Nomination and remuneration committee

Additional Position
Member
Director DIN
00010484
Member Name
Shyam Sunder Bhartia
Position
Non-Executive - Non Independent Director

Nomination and remuneration committee

Additional Position
Member
Director DIN
00101328
Member Name
Vivek Mehra
Position
Non-Executive - Independent Director

Nomination and remuneration committee

Additional Position
Member
Director DIN
00204434
Member Name
Arun Seth
Position
Non-Executive - Independent Director

Nomination and remuneration committee

Risk Management Committee

Additional Position
Member
Director DIN
00101328
Member Name
Vivek Mehra
Position
Non-Executive - Independent Director

Risk Management Committee

Additional Position
Member
Director DIN
01313356
Member Name
Shivpriya Nanda
Position
Non-Executive - Independent Director

Risk Management Committee

Additional Position
Member
Director DIN
00824227
Member Name
Harsh Mahajan
Position
Non-Executive - Independent Director

Risk Management Committee

Additional Position
Chairperson
Director DIN
00309302
Member Name
Sushil Kumar Roongta
Position
Non-Executive - Independent Director

Risk Management Committee

Additional Position
Member
Director DIN
00204434
Member Name
Arun Seth
Position
Non-Executive - Independent Director

Risk Management Committee

Additional Position
Member
Director DIN
02219458
Member Name
Shirish Gundopant Belapure
Position
Non-Executive - Independent Director

Risk Management Committee

Additional Position
Member
Director DIN
00020603
Member Name
Priyavrat Bhartia
Position
Executive Director

Risk Management Committee

Additional Position
Member
Director DIN
03019690
Member Name
Arjun Shanker Bhartia
Position
Executive Director

Risk Management Committee

Stakeholders Relationship Committee

Additional Position
Chairperson
Director DIN
00204434
Member Name
Arun Seth
Position
Non-Executive - Independent Director

Stakeholders Relationship Committee

Additional Position
Member
Director DIN
00020603
Member Name
Priyavrat Bhartia
Position
Executive Director

Stakeholders Relationship Committee

Additional Position
Member
Director DIN
00824227
Member Name
Harsh Mahajan
Position
Non-Executive - Independent Director

Stakeholders Relationship Committee

Additional Position
Member
Director DIN
01313356
Member Name
Shivpriya Nanda
Position
Non-Executive - Independent Director
Entry MainD
Gap Between The Meetings Of The Risk Management Committee
Yes
Meeting Of Audit Committee
Yes
Meeting Of Board Of Directors
Yes
Meeting Of Independent Directors
Yes
Meeting Of Nomination And Remuneration Committee
Yes
Meeting Of Risk Management Committee
Yes
Meeting Of Stakeholders Relationship Committee
Yes
Quorum Of Board Meeting
Yes
Quorum Of Nomination And Remuneration Committee Meeting
Yes
Quorum Of Risk Management Committeemeeting
Yes
The Meetings Of The Board Of Directors And The Above Committees Have Been Conducted In The Manner As Specified In Sebi Regulations2015
Yes
Entry MeetingBOD1
Dates Of Meeting In The Previous Quarter
31-Oct-2025
Number Of Directors Present In Meeting Of Board Of Directors
10
Number Of Independent Directors Attending The Meeting
6
Total Number Of Directors As On Date Of The Meeting
10
Entry MeetingBOD2
Dates Of Meeting If Any In The Relevant Quarter
06-Feb-2026
Maximum Gap Between Any Two Consecutive Meetings
97
Number Of Directors Present In Meeting Of Board Of Directors
10
Number Of Independent Directors Attending The Meeting
6
Total Number Of Directors As On Date Of The Meeting
10
Entry MeetingComit1
Dates Of Meeting Of The Committee In The Previous Quarter
31-Oct-2025
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
4
Number Of Independent Director Attending Meeting Of Committee
4
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
4
Entry MeetingComit2
Dates Of Meeting Of The Committee In The Relevant Quarter
05-Feb-2026
Maximum Gap Between Any Two Consecutive Meetings
96
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
4
Number Of Independent Director Attending Meeting Of Committee
4
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
4
Entry MeetingComit3
Dates Of Meeting Of The Committee In The Previous Quarter
31-Oct-2025
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
4
Number Of Independent Director Attending Meeting Of Committee
3
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
4
Entry MeetingComit4
Dates Of Meeting Of The Committee In The Previous Quarter
03-Dec-2025
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
7
Number Of Independent Director Attending Meeting Of Committee
6
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
8
Entry MeetingComit5
Dates Of Meeting Of The Committee In The Previous Quarter
03-Dec-2025
Number Of Director Present In Meeting Of Committee All Directors Including Independent Director
6
Number Of Independent Director Attending Meeting Of Committee
5
Number Of Member Attending Meeting Of Committee
0
Total Number Of Directors As On Date Of The Meeting
7
Entry MainD
Contact Information Of The Designated Officials Of The Listed Entity Who Are Responsible For Assisting And Handling Investor Grievances
Yes
Disclosure Web Link Of Company At Which Contact Information Of The Designated Officials Of The Listed Entity Who Are Responsible For Assisting And Handling Investor Grievances Is Placed
https://www.jubilantpharmova.com/investors/investor-contact/investor-grievances
Disclosure Web Link Of Company At Which Email Address For Grievance Redressal And Other Relevant Details Is Placed
https://www.jubilantpharmova.com/investors/investor-contact/investor-grievances
Email Address For Grievance Redressal And Other Relevant Details
Yes
No Of Investor Complaints Disposed Off During The Period
3
No Of Investor Complaints During The Period
0
No Of Investor Complaints Received During The Period
3
Whether Part B Of Annexure I Of The SEBI Circular Dated31December2024Related To Investor Grievance Redressal Report Is Applicable To The Entity
Yes
Entry MainI
No Of Investor Complaints
0
Entry PY_I
No Of Investor Complaints
0
Entry D_AcquisitionShares1
Percentage Of Shares Or Voting Rights Acquired During The Quarter
0
Entry I_AcquisitionShares_PY1
Percentage Of Aggregate Holding Of Shares Or Voting Rights
0.1755
Entry I_AcquisitionShares1
Date Of Acquisition
29-Jan-2026
Name Of The Unlisted Company In Which Shares Or Voting Rights Have Been Acquired
Forum I Aviation Private Limited
Percentage Of Aggregate Holding Of Shares Or Voting Rights
0.1755
Entry MainD
Any Other Information For Disclosure Of Acquisition Of Shares Or Voting Rights In Unlisted Companies Explanatory Text Block
Acquisition of 92,56,291 Equity Shares of Forum 1 Aviation Private Limited through Rights Issue.
Composition Of Board Of Directors Of Unlisted Material Subsidiary
Yes
Whether Part C Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Acquisition Of Shares Or Voting Rights In Unlisted Companies Is Applicable To The Entity
Yes
Entry I_OngoingTaxLitigationsOrDisputes1
Current Status
No change. Jubilant Pharmova Limited expects to get relief from the Appellate Authority and does not anticipate any material adverse financial implication
Date of Initiation
28-Mar-2017
Opposing Party
Income Tax Department
Status (Previous Disclosure)
Appeal filed by Jubilant Pharmova Limited and pending before CIT (Appeals) w.r.t. notional adjustments under India Transfer Pricing Rules in relation to international transactions with Associated Enterprises - Rs. 58.15 crs for various years Date of Initiation of Litigation " 28/02/2022 (FY 09 and FY 10); 13/05/2022 (FY 11); 20/09/2017 (FY 12); 28/03/2017 (FY 13); 17/04/2018 (FY 14); 22/02/2019 (FY 15)
Entry I_OngoingTaxLitigationsOrDisputes2
Current Status
No change. Jubilant Pharmova Limited expects Hon'ble ITAT, Delhi to sustain the order of CIT- Appeals and does not anticipate any material adverse financial implication
Date of Initiation
20-Sep-2017
Opposing Party
Jubilant Pharmova Limited
Status (Previous Disclosure)
Appeal filed by Income Tax Department against Jubilant Pharmova Limited and pending before Income Tax Appellate Tribunal (ITAT) w.r.t. notional adjustments under India Transfer Pricing Rules in relation to international transactions with Associated Enterprises - Rs. 9.47 crs
Entry I_OngoingTaxLitigationsOrDisputes3
Current Status
No change. Order for AY 15-16 has been quashed by CIT(A). For AY 16-17, 17-18 and 18-19. Revised Tax effect is Rs.4.32 crs.
Date of Initiation
24-Apr-2024
Opposing Party
Income Tax Department
Status (Previous Disclosure)
Appeal filed before CIT(Appeals) against order passed u/s 153C for various years, the tax effect of which is Rs. 4.43 crs.
Entry I_OngoingTaxLitigationsOrDisputes4
Current Status
No change. Jubilant Biosys Limited expects Hon'ble Allahabad High Court to sustain the order of the Hon'ble ITAT, Delhi and does not anticipate any material adverse financial implication
Date of Initiation
24-Apr-2019
Opposing Party
Jubilant Biosys Limited, a wholly owned Indian subsidiary of Jubilant Pharmova Limited
Status (Previous Disclosure)
Appeal filed by Income Tax Department against Jubilant Biosys Limited and pending before Allahabad High Court w.r.t. denial of deduction with respect to payment to related party by invoking the provision of section 80IB (13) r.w. section 80IA (10) of the Act and disallowance of entire expenditure debited in P & L account by treating the same as Capital expenditure - Rs.228.87 crs
Entry I_OngoingTaxLitigationsOrDisputes5
Current Status
Case for AY 20-21 has been quashed by ITAT subject to certain caveats.
Date of Initiation
20-Sep-2024
Opposing Party
Income Tax Department
Status (Previous Disclosure)
Appeal filed by Jubilant Generics Limited (wholly owned subsidiary of Jubilant Pharmova Limited) and pending before Income Tax Appellate Tribunal (ITAT) w.r.t. notional adjustments under India Transfer Pricing Rules in relation to international transactions with Associated Enterprises. For FY 18 matter has been remanded back by ITAT to file of the AO for evaluation . Date of Initiation of Litigation 25-08-2022 (FY 18); 20-09-2024 (FY 20). Tax impact of the adjustments on carried forward losses is Rs 36.03 crores basis the prevalent tax rates.
Entry I_OngoingTaxLitigationsOrDisputes6
Current Status
No change. Jubilant Pharmova Limited expects to get relief from the Appellate Authority and does not anticipate any material adverse financial implication
Date of Initiation
27-Dec-2025
Opposing Party
Income Tax Department
Status (Previous Disclosure)
Tax demand of Rs. 22.10 crs vide orders passed in AY 20-21 . Demand primarily arising on account of arithmetical errors and mistakes apparent from records apart from certain disallowances of deductions and transfer pricing adjustments ignoring the contentions of the company. Company expects the deletion of Tax Demand of Rs. 22.10 crs in due course. Appeal filing process before ITAT is under process.
Entry MainD
Whether Part E Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Updates To Ongoing Tax Litigations Or Disputes Is Applicable To The Entity
Yes
Reason For Part D Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Imposition Of Fine Or Penalty Is Not Applicable To The Entity
There was no fine and penalty for the quarter ended March 31, 2026, requiring disclosure under this report.
Whether Part D Of Annexure I Of The SEBI Circular Dated31December2024Related To Disclosure Of Imposition Of Fine Or Penalty Is Applicable To The Entity
No